Each Small Business Technology Transfer (STTR) grant allows for non-dilutive support for research and development
PRINCETON, NEW JERSEY (January 24, 2024) — Inaedis, Inc., a new platform biotechnology company, received nearly $600,000 in non-dilutive support for research and development from the U.S. National Science Foundation (NSF) and the National Center for Advancing Translational Sciences (NCATS) at the U.S. National Institutes of Health (NIH).
The two grants are part of the NIH and NSF’s Small Business Technology Transfer (STTR) Phase I programs, which award grants to small businesses engaged in research and development for commercialization. Inaedis is tackling the vulnerabilities of cold chain systems, enabling the pharmaceutical industry to handle liquid biologics at room temperature so they can be transported and stored anywhere in the world as durable powders.
“By offering a robust solution for thermal stabilization, the technology will have far-reaching effects on population health and immunization,” the NSF award stated. “The research and development establishes the efficacy, reliability, and applicability of rapid Room Temperature Aerosol Dehydration (RTAD) as a commercially promising platform for the dehydration of various biologic drug molecules.”
This funding will allow Inaedis to continue researching RTAD, which can be applied to biologics and life-saving drugs, reducing wastage of pharmaceuticals by at least $30 billion.
“We realized during the Covid-19 pandemic that vaccine logistics are just as important for saving lives as the vaccines themselves,” said Inaedis founder and CEO Dr. Maksim Mezhericher. “As a global leader in biotechnology, the United States has an incredible opportunity to promote rapid powderization of liquid biologics and vaccines to improve the transport and delivery of live-saving treatments.”
Inaedis, Inc.
Inaedis, Inc. is a spin-out company from Princeton University developing a pharmaceutical platform changing the future of drug development, delivery, and distribution by powderizing life-saving vaccines and biologics.
First developed by Princeton scientists during the Covid-19 pandemic, our goal is to give everyone access to the miracles of modern medicine. Our proprietary Rapid Room-Temperature Dehydration (RTAD) platform technology finally solves the global dilemma posed by the thermal stabilization requirements of life-saving heat and freeze-sensitive vaccines and biologics.
Inaedis is led by its founders: CEO Dr. Maksim Mezhericher and Prof. Howard A. Stone and is backed by Roadrunner Venture Studios and Princeton Innovation Center.
Media Contact: Maksim Mezhericher, maksim@inaedis.com
Research reported in this publication was supported by the National Center For Advancing Translational Sciences of the National Institutes of Health under Award Number R41TR004571. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.